Transgenomic to Provide PGx Services to Two Drug Developers | GenomeWeb

NEW YORK (GenomeWeb News) - Transgenomic said yesterday that it has struck agreements with two undisclosed pharmaceutical companies to provide genetic mutation discovery services for two Phase II clinical trials.

The company said the deals will be worth a total of $500,000 in the first half of 2008, but it did not disclose the names of the companies involved or provide further financial details.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.